Hope for kidney health in gout drug

PERL study will explore the potential of allopurinol to delay or halt kidney disease in people with type 1 diabetes. As we near the end of March, National Kidney Month, we find ourselves at the beginning stages of an exciting new clinical trial that could lead to better health for people with type 1 diabetes […]

Merck smart insulin project advancing into clinical trials

On May 6, 2014, Merck held an investor briefing and provided updates on various strategic initiatives, including its smart insulin project acquired in 2010 when it purchased SmartCells. SmartCells — a diabetes drug-development company that received early support from JDRF — was founded in 2003 by Todd Zion, Ph.D., an MIT chemical engineer who had […]

Redefining the Diagnosis of Type 1 Diabetes

Updated criteria could open new possibilities for intervention before symptoms appear JDRF is leading a pertinent discussion in the diabetes field about what defines a diagnosis of type 1 diabetes (T1D). At the 14th Annual Rachmiel Levine Diabetes and Obesity Symposium today, Richard Insel, M.D., JDRF’s chief scientific officer, reviewed evidence supporting the need to […]

Potential drugs for beta cell regeneration discovered

At the April 2014 JDRF-GNF (Genomics Institute of the Novartis Research Foundation) meeting, Dr. Byran Laffitte described how GNF has the potential to identify the first disease altering therapy for T1D. He presented preclinical evidence that GNF has identified the first highly effective low molecular weight regulators of beta cell proliferation. Overall, GNF has identified […]

Progress on ViaCyte’s novel encapsulated cell therapy

In February, JDRF announced it is providing additional milestone-based funding for the continued development of ViaCyte’s VC-01™ encapsulated cell therapy product candidate for the treatment of T1D. JDRF will fund up to $7 million to help ensure a rapid transition of the project into the clinical phase of development once ViaCyte’s investigational new drug application […]

Creating a world without type 1 diabetes

We’re the plan to change the future type. JDRF research focuses on key therapies that hold significant promise in turning Type One into Type None, including: artificial pancreas, encapsulation, smart insulin, restoration, and prevention.

Broadening T1D R&D funding sources

Last year JDRF took a number of significant actions to broaden the resources available in the T1D research and development space – three of them are highlighted here. Each of these will help speed progress towards our research goals across our portfolio of research objectives to develop and deliver novel T1D therapies to patients. In […]

New JDRF-funded study will evaluate potential benefits of metformin for type 1 diabetes

A new JDRF-funded study will evaluate whether metformin—a drug commonly used to treat type 2 diabetes (T2D)—combined with standard insulin therapy could safely improve blood-glucose control in overweight children and adolescents with type 1 diabetes (T1D). For more than 50 years, metformin has proven safe and effective in helping to control blood-glucose levels in people […]